Merck's Keytruda Offers Hope And Risk In Early Breast Cancer
Executive Summary
I-SPY2 study shows promising efficacy for PD-1 inhibitor Keytruda in combination with chemo in high-risk breast cancer – including a tripling of response rate in triple-negative breast cancer – but also raises red flag on immune-mediated adverse events in early-stage patients.
You may also be interested in...
Keytruda Poised To Add Early TNBC To Its Resumé As KEYNOTE-522 Hits First Endpoint
A first look at data from Merck & Co’s KEYNOTE-522 trial of Keytruda in early triple-negative breast cancer showed significant pathological response rates and hinted at good things to come in event-free survival, but experts at ESMO want more mature data.
Roche's Tecentriq Steals Lead In Triple-Negative Breast Cancer
The PD-L1 inhibitor is the first checkpoint immunotherapy to gain approval in the tough-to-treat disease setting.
Pivotal Data Put Roche's Kadcyla In Position For Earlier Breast Cancer
KATHERINE supports filings for earlier use of Kadyla in adjuvant setting of breast cancer.